{"id":56438,"date":"2020-10-05T10:25:52","date_gmt":"2020-10-05T08:25:52","guid":{"rendered":"http:\/\/www.pcb.ub.edu\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\/"},"modified":"2021-05-19T08:31:59","modified_gmt":"2021-05-19T07:31:59","slug":"connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/es\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\/","title":{"rendered":"Connecta Therapeutics levanta 1,7 M \u20ac para desarrollar un nuevo tratamiento del s\u00edndrome de X fr\u00e1gil"},"content":{"rendered":"<p><strong><a href=\"http:\/\/www.pcb.ub.edu\/es\/empresa\/connecta-therapeutics\/\" target=\"_blank\" rel=\"noopener noreferrer\">Connecta Therapeutics<\/a> ha cerrado una ronda de inversi\u00f3n de 1,7 millones de euros liderada por <a href=\"https:\/\/inveready.com\" target=\"_blank\" rel=\"noopener noreferrer\">Inveready<\/a>.\u00a0Esta inyecci\u00f3n de capital le permitir\u00e1 llevar su primer f\u00e1rmaco hasta la etapa de estudio cl\u00ednico de Fase\u00a0IIa\u00a0en pacientes con s\u00edndrome de X fr\u00e1gil (SXF), el tipo m\u00e1s com\u00fan de discapacidad intelectual hereditaria.\u00a0La biotecnol\u00f3gica, una\u00a0spin-off\u00a0del\u00a0<a href=\"https:\/\/prousresearch.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">Prous Institute for Biomedical Research,\u00a0<\/a>\u00a0se fund\u00f3 en el Parc Cient\u00edfic\u00a0de Barcelona en 2019 para desarrollar\u00a0nuevas terapias que cubran necesidades m\u00e9dicas no resueltas\u00a0del sistema nervioso central, y actualmente sigue vinculada al Parque como entidad asociada.<\/strong><\/p>\n<p>Inveready ha liderado primera ronda de inversi\u00f3n de Connecta Therapeutics, en la cual tambi\u00e9n han participado el Centro para el Desarrollo Tecnol\u00f3gico Industrial (CDTI) \u2013a trav\u00e9s del programa Innvierte ,destinado a empresas tecnol\u00f3gicas e innovadoras espa\u00f1olas\u2013, Josep Prous y David Prous, socios fundadores del Prous Institute for Biomedical Research,\u00a0y Jordi F\u00e0brega, ex director de Desarrollo de Negocio en Biocat.<\/p>\n<p>El SXF es la forma m\u00e1s com\u00fan de discapacidad intelectual hereditaria. Actualmente, se diagnostica mediante pruebas sangu\u00edneas de ADN, pero no existe un tratamiento espec\u00edfico dirigido a la causa de la patolog\u00eda, s\u00f3lo tratamientos que ayudan a paliar sus s\u00edntomas. Los pacientes con SXF tienen afectada la neuroplasticidad, es decir, la propiedad del cerebro para recuperarse y reestructurarse desde el punto de vista molecular y celular. La neuroplasticidad es clave para el desarrollo y el aprendizaje, y su afectaci\u00f3n provoca en estos pacientes una disminuci\u00f3n en la capacidad intelectual (desde leve hasta el retraso mental severo) y\u00a0les genera problemas sociales y conductuales (d\u00e9ficit de atenci\u00f3n, hiperactividad, autismo, etc.).<\/p>\n<p>El f\u00e1rmaco de Connecta Therapeutics ha demostrado en estudios precl\u00ednicos ser un buen modulador de la neuroplasticidad, mejora la capacidad cognitiva y restaura caracter\u00edsticas de autismo tales como los problemas de interacci\u00f3n social. \u201cEstamos muy satisfechos con la incorporaci\u00f3n de Inveready y el CDTI en la compa\u00f1\u00eda no s\u00f3lo como socios inversores y estrat\u00e9gicos, sino por su experiencia en el impulso de proyectos con gran impacto en I+D. Queremos llevar este f\u00e1rmaco <em>first-in-class<\/em> lo antes posible a ensayos cl\u00ednicos para comprobar la eficacia de esta estrategia terap\u00e9utica para el SXF\u201d, explica Jordi F\u00e0brega, CEO de Connecta Therapeutics. La compa\u00f1\u00eda prev\u00e9 iniciar los ensayos de Fase I a finales de 2021 y los de Fase IIa en 2023.<\/p>\n<p>\u201cEl valor diferencial de este f\u00e1rmaco es que act\u00faa a trav\u00e9s de la modulaci\u00f3n de m\u00faltiples prote\u00ednas implicadas en las anomal\u00edas de la estructura de las espinas sin\u00e1pticas de las neuronas corticales del SXF\u201d destaca la Dra. Mara Dierssen, asesora en investigaci\u00f3n de Connecta Therapeutics. De esta forma, el f\u00e1rmaco puede hacer frente a los problemas que suelen limitar la utilidad cl\u00ednica de muchos tratamientos farmacol\u00f3gicos, especialmente en el sistema nervioso central. La Dra. Dierssen dirige el grupo de Neurobiolog\u00eda Celular y de Sistemas del Centro de Regulaci\u00f3n Gen\u00f3mica (CRG), reconocido internacionalmente por sus descubrimientos pioneros en discapacidad intelectual y s\u00edndrome de Down, y ha participado activamente en el desarrollo precl\u00ednico del f\u00e1rmaco.<\/p>\n<p>Para Inveready esta es la octava inversi\u00f3n de su fondo Biotech III. Sara Secall, Operating Partner &amp; Life Sciences Investment Director de Inveready, remarca que \u201cde Connecta nos gust\u00f3 la solvencia y audacia del equipo emprendedor, as\u00ed como los resultados precl\u00ednicos. El f\u00e1rmaco se dirige a una clara necesidad del mercado y adem\u00e1s tiene un perfil de extensi\u00f3n a otros trastornos del neurodesarrollo\u201d.<\/p>\n<p>La modulaci\u00f3n de la neuroplasticidad tambi\u00e9n podr\u00eda ser una estrategia efectiva en otros trastornos del sistema nervioso central ya que se ha observado una afectaci\u00f3n de \u00e9sta en pacientes que presentan una disminuci\u00f3n de la capacidad intelectual y problemas de conducta. En este sentido, el f\u00e1rmaco de Connecta Therapeutics podr\u00eda ser efectivo en indicaciones como\u00a0el s\u00edndrome de Rett, el s\u00edndrome de Down o trastornos del espectro autista.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Connecta Therapeutics ha cerrado una ronda de inversi\u00f3n de 1,7 millones de euros liderada por Inveready.\u00a0Esta inyecci\u00f3n de capital le permitir\u00e1 llevar su primer f\u00e1rmaco hasta la etapa de estudio&#8230;<\/p>\n","protected":false},"author":2,"featured_media":56417,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[],"tags":[],"class_list":["post-56438","post","type-post","status-publish","format-standard","has-post-thumbnail"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Connecta Therapeutics levanta 1,7 M \u20ac para desarrollar un nuevo tratamiento del s\u00edndrome de X fr\u00e1gil - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/es\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Connecta Therapeutics levanta 1,7 M \u20ac para desarrollar un nuevo tratamiento del s\u00edndrome de X fr\u00e1gil - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Connecta Therapeutics ha cerrado una ronda de inversi\u00f3n de 1,7 millones de euros liderada por Inveready.\u00a0Esta inyecci\u00f3n de capital le permitir\u00e1 llevar su primer f\u00e1rmaco hasta la etapa de estudio...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/es\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2020-10-05T08:25:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-05-19T07:31:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2020\/11\/Connecta-Therapeutics.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"PCB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"PCB\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\\\/\"},\"author\":{\"name\":\"PCB\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/b10afd334ced9516cc2d58c87f31aae9\"},\"headline\":\"Connecta Therapeutics levanta 1,7 M \u20ac para desarrollar un nuevo tratamiento del s\u00edndrome de X fr\u00e1gil\",\"datePublished\":\"2020-10-05T08:25:52+00:00\",\"dateModified\":\"2021-05-19T07:31:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\\\/\"},\"wordCount\":711,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/Connecta-Therapeutics.jpeg\",\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\\\/\",\"name\":\"Connecta Therapeutics levanta 1,7 M \u20ac para desarrollar un nuevo tratamiento del s\u00edndrome de X fr\u00e1gil - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/Connecta-Therapeutics.jpeg\",\"datePublished\":\"2020-10-05T08:25:52+00:00\",\"dateModified\":\"2021-05-19T07:31:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/b10afd334ced9516cc2d58c87f31aae9\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/Connecta-Therapeutics.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/Connecta-Therapeutics.jpeg\",\"width\":900,\"height\":330,\"caption\":\"David Prous, Jordi F\u00e0brega y Josep Prous, cofundadores de Connecta Therapeutics, con Sara Secall de Inveready (Foto: Connecta Therapeutics).\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Connecta Therapeutics levanta 1,7 M \u20ac para desarrollar un nuevo tratamiento del s\u00edndrome de X fr\u00e1gil\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/b10afd334ced9516cc2d58c87f31aae9\",\"name\":\"PCB\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4cf197ef9a9d2755c82c1c27b53e47de6928d5b0825c3d34a4fa0f83f91ea378?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4cf197ef9a9d2755c82c1c27b53e47de6928d5b0825c3d34a4fa0f83f91ea378?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4cf197ef9a9d2755c82c1c27b53e47de6928d5b0825c3d34a4fa0f83f91ea378?s=96&d=mm&r=g\",\"caption\":\"PCB\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/author\\\/pcb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Connecta Therapeutics levanta 1,7 M \u20ac para desarrollar un nuevo tratamiento del s\u00edndrome de X fr\u00e1gil - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/es\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\/","og_locale":"es_ES","og_type":"article","og_title":"Connecta Therapeutics levanta 1,7 M \u20ac para desarrollar un nuevo tratamiento del s\u00edndrome de X fr\u00e1gil - Parc Cient\u00edfic de Barcelona","og_description":"Connecta Therapeutics ha cerrado una ronda de inversi\u00f3n de 1,7 millones de euros liderada por Inveready.\u00a0Esta inyecci\u00f3n de capital le permitir\u00e1 llevar su primer f\u00e1rmaco hasta la etapa de estudio...","og_url":"https:\/\/www.pcb.ub.edu\/es\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2020-10-05T08:25:52+00:00","article_modified_time":"2021-05-19T07:31:59+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2020\/11\/Connecta-Therapeutics.jpeg","type":"image\/jpeg"}],"author":"PCB","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"PCB","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/es\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\/"},"author":{"name":"PCB","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/b10afd334ced9516cc2d58c87f31aae9"},"headline":"Connecta Therapeutics levanta 1,7 M \u20ac para desarrollar un nuevo tratamiento del s\u00edndrome de X fr\u00e1gil","datePublished":"2020-10-05T08:25:52+00:00","dateModified":"2021-05-19T07:31:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\/"},"wordCount":711,"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2020\/11\/Connecta-Therapeutics.jpeg","inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/es\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\/","url":"https:\/\/www.pcb.ub.edu\/es\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\/","name":"Connecta Therapeutics levanta 1,7 M \u20ac para desarrollar un nuevo tratamiento del s\u00edndrome de X fr\u00e1gil - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2020\/11\/Connecta-Therapeutics.jpeg","datePublished":"2020-10-05T08:25:52+00:00","dateModified":"2021-05-19T07:31:59+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/b10afd334ced9516cc2d58c87f31aae9"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/es\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/es\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.pcb.ub.edu\/es\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2020\/11\/Connecta-Therapeutics.jpeg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2020\/11\/Connecta-Therapeutics.jpeg","width":900,"height":330,"caption":"David Prous, Jordi F\u00e0brega y Josep Prous, cofundadores de Connecta Therapeutics, con Sara Secall de Inveready (Foto: Connecta Therapeutics)."},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/es\/connecta-therapeutics-levanta-17-m-e-para-desarrollar-un-nuevo-tratamiento-del-sindrome-de-x-fragil\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/es\/"},{"@type":"ListItem","position":2,"name":"Connecta Therapeutics levanta 1,7 M \u20ac para desarrollar un nuevo tratamiento del s\u00edndrome de X fr\u00e1gil"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/b10afd334ced9516cc2d58c87f31aae9","name":"PCB","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/4cf197ef9a9d2755c82c1c27b53e47de6928d5b0825c3d34a4fa0f83f91ea378?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4cf197ef9a9d2755c82c1c27b53e47de6928d5b0825c3d34a4fa0f83f91ea378?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4cf197ef9a9d2755c82c1c27b53e47de6928d5b0825c3d34a4fa0f83f91ea378?s=96&d=mm&r=g","caption":"PCB"},"url":"https:\/\/www.pcb.ub.edu\/es\/author\/pcb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/56438","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=56438"}],"version-history":[{"count":19,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/56438\/revisions"}],"predecessor-version":[{"id":56478,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/56438\/revisions\/56478"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media\/56417"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=56438"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/categories?post=56438"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/tags?post=56438"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}